If I had to Rip Van Winkle my portfolio (buy, never look) for 10 yrs, I'd pick:
1. $IREN
2. $GLXY
3. $SPCX
4. $TSLA
5. $PLTR
6. Anduril (via secondaries)
7. $OPEN
8. $HIMS
9. $AMZN
10. bitcoin:native
I don't own all those currently, but I intend to as I rotate over time.
Increasingly thinking $IREN's new leading frontier lab deal *might* be for more than just 2026 capacity.
I could be wrong so NFA / DYOR.
*IREN repeated that $4.0B of 2026 capacity is signed multiple times. Zero mention of the $4.7B contracted inclusive of 2027 capacity sold to
Easy win for $IREN IR: if Batch Zero baseload for SW2 and potentially other sites is confirmed on Monday, PR it. Batch Zero baseload is an extremely material moat and has been a drag on Texas based DC players all year. There is no world in which it's not material enough to PR.
Solid $IREN EC. At this point, Satya, Jensen, and Bezos (via Prometheus) are all customers - how many names like that are required before market realizes IREN is a serious player? And IREN added a leading frontier lab - there aren't many of those.
Active discussions at $25M per
Bullish for $HIMS. When diagnostics is less and less differentiated, connecting diagnostics to distribution at scale matters greatly.
https://t.co/PMLw13U0WS
Crude TA is sometimes my favorite TA. When I look at $IREN over the past year, after the first big re-rate, we've had three consecutive EC runups and post-EC dumps, with this pre-EC PA behaving differently post-Leopold flush. Why? Seems clear the cap table's fundamentally
Everybody wants the wen deal candle but the largest re-rate typically comes when the largest pools of capital allocate. As $IREN delivers more Horizons and approaches it's ~$4B+ end of year ARR target, the quarterly revenue and operating cash flows (before capex, which is
